

Bristol-Myers Squibb Co.: PharmaVitae Profile

<https://marketpublishers.com/r/BC96C108490EN.html>

Date: March 2011

Pages: 84

Price: US\$ 5,700.00 (Single User License)

ID: BC96C108490EN

Abstracts

Introduction

This analysis examines the historical and forecast performance for Bristol-Myers Squibb in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs.

Features and benefits

Gain insight into Bristol-Myers Squibb's strategic outlook across the next 6 years

Analyze company sales forecasts by product, therapy area, lifecycle stage, geography, molecule type and source

Highlights

Strategic insight into the prospects for BMS over the next six years. Picking out key strengths, weaknesses, opportunities and threats and evaluating the company's prescription pharmaceuticals outlook using a variety of cuts of the historical and forecast sales.

Your key questions answered

Benchmark BMS's performance against key rivals in the prescription pharmaceutical sector

Determine the value of BMS's pipeline and other strategies the company is taking to counteract an imminent wave of generic competition.

Assess what makes BMS a model biopharma company and why its newfound focus could lead to the industry's next megamerger.

Contents

Executive Summary

Key findings

Bristol-Myers Squibb prescription pharma sales outlook

Bristol-Myers Squibb financial outlook

Key developments

[Missing title]

Upcoming developments

SWOT analysis

Strengths

Weaknesses

Opportunities

Threats

About

ABOUT THIS PROFILE

PharmaVitae Explorer database

Chapter structure

Strategic Insight

Company Introduction

Company Sales

Company Financials

Key Products

Data sourcing

Analyst consensus

STRATEGIC INSIGHT

Key findings

Strategic insight

BMS expiry decline fastest of Big Pharma

COMPANY INTRODUCTION

Key findings

Background

Key corporate developments

Squibb

Bristol-Myers Squibb

M&A strategy

M&A history

M&A strategy

SALES ANALYSIS

Key findings

Prescription pharmaceutical sales and growth rate analysis, 2004–16

Product analysis

Product analysis, 2004–10

Product analysis, 2010–16

Therapy area analysis

Geographic analysis
Launch/core/expiry analysis
 Launch analysis, 2010–16
 Core analysis, 2010–16
 Expiry analysis, 2010–16
 Launch/core/expiry configuration, 2010–16
Molecule type analysis
Externalization analysis

FINANCIAL ANALYSIS

Key findings
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2004-10
Operating costs and profit analysis
 Operating performance analysis, 2004–10
 Operating performance analysis, 2010–16

PRODUCT ANALYSIS

Overview
 Plavix
 Sprycel
 Orencia
 Reyataz
 Baraclude
 Onglyza
 Nulojix
 Sustiva
 Dapagliflozin
Bristol-Myers Squibb pipeline overview

APPENDIX

Abbreviations
Exchange rates

I would like to order

Product name: Bristol-Myers Squibb Co.: PharmaVitae Profile

Product link: <https://marketpublishers.com/r/BC96C108490EN.html>

Price: US\$ 5,700.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/BC96C108490EN.html>